One shot, six months of malaria shield? a new trial tests a powerful antibody in children

This trial tests whether a single dose of an experimental antibody, L9LS, can prevent malaria in children who have just been hospitalized with severe malaria or severe anemia. These children face a high risk of getting sick again for months after leaving the hospital. The study compares the antibody to the current standard of care—three monthly courses of preventive malaria pills. If the antibody works as well or better, it could offer a simpler, longer-lasting way to protect these vulnerable children.